20 completed, 8 unknown, 2 not yet recruiting, 2 terminated. 32 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 32 | Completed 20, Unknown 8, Not yet recruiting 2, Terminated 2 |
| Phase 2 | 6 | Completed 3, Unknown 2, Not yet recruiting 1 |
Follow Bacterial Vaginosis: new trials by email Literature Review of Bacterial Vaginosis trials Research Report on Bacterial Vaginosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AUTOP 2: Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm Birth Vaginal flora abnormalities screening and quantification using molecular biology technique, Azithromycin, Ceftriaxone - Bacterial Vaginosis, Vaginal Dysbiosis | Phase 3 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 1794 | 2026-10-01 | 2026-08-27 |
| Study to Evaluate Efficacy and Safety of Gyntima® Balance in Preventing Recurrences of Bacterial Vaginosis Lactobacillus gasseri KABP®064 10e9 CFU/capsule, Placebo (maltodextrin) - Vaginosis, Bacterial, Bacterial Vaginosis | Phase 2 / Phase 3 | Not yet recruiting | Kaneka Americas Holding Inc. | 160 | 2026-04-01 | 2026-04-14 |
| Effect of PreforPro® on Urinary and Vaginal Health Preforpro, Placebo - Bacterial Vaginosis, Bacterial Infections | Phase 3 | Unknown | Jeremy Burton | 50 | 2024-05-01 | 2024-01-09 |
| Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL Ovule EVEGYN A, EVEGYN B, Gynomax® XL Vaginal Ovule - Trichomonal Vaginitis, Bacterial Vaginosis | Phase 3 | Completed | Ege University | 577 | 2020-07-20 | 2023-09-28 |
| DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE) DARE-BV1clindamycin phosphate vaginal gel, 2% - Bacterial Vaginosis | Phase 3 | Completed | Daré Bioscience, Inc. | 307 | 2020-06-16 | 2022-12-08 |
| Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis GDC-229, Metronidazole Vaginal Gel 0.75%, Placebo - Bacterial Vaginosis | Phase 3 | Completed | Balmoral Medical company | 871 | 2017-03-10 | 2020-01-07 |
| Efficacy and Safety Study of Metronidazole, Nystatin and Dexamethasone Combination Therapy in Bacterial and Fungal Vaginal Infections Association of metronidazole; nystatin and dexamethasone, Flagyl - Bacterial Vaginosis, Fungal Vaginal Infections | Phase 3 | Unknown | Marjan Industria e Comercio ltda | 160 | 2016-01-01 | 2015-04-09 |
| Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219 SYM-1219 - Bacterial Vaginosis | Phase 3 | Completed | Symbiomix Therapeutics | 325 | 2015-06-01 | 2021-04-13 |
| A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis SYM-1219, Placebo - Bacterial Vaginosis | Phase 3 | Completed | Symbiomix Therapeutics | 189 | 2015-05-28 | 2021-10-15 |
| Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV) Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel - Bacterial Vaginosis | Phase 3 | Completed | Starpharma Pty Ltd | 586 | 2014-10-13 | 2019-07-22 |
| Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV) Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel - Bacterial Vaginosis | Phase 3 | Completed | Starpharma Pty Ltd | 637 | 2014-10-03 | 2018-06-25 |
| Safety and Efficacy Study of Gynevac Lactobacillus Vaccine in the Treatment of Bacterial Vaginosis Gynevac, Placebo - Bacterial Vaginosis | Phase 3 | Unknown | Amvac Kft. | 240 | 2014-06-01 | 2014-10-29 |
| BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) Study Placebo, Boric acid, Metronidazole - Bacterial Vaginosis | Phase 2 / Phase 3 | Completed | University of British Columbia | 13 | 2014-04-01 | 2016-10-27 |
| A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women clindamycin phosphate vaginal cream 2%, placebo - BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include | Phase 3 | Completed | Actavis Inc. | 604 | 2014-01-01 | 2020-01-28 |
| Safety and Efficacy Study to Treat Bacterial Vaginosis Product 55394, Placebo Vehicle (non-treatment) - Bacterial Vaginosis | Phase 3 | Completed | Medicis Global Service Corporation | 651 | 2012-05-01 | 2013-08-21 |
| A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis 1% SPL7013 Gel, Placebo - Bacterial Vaginosis | Phase 3 | Completed | Starpharma Pty Ltd | 251 | 2012-04-17 | 2019-07-17 |
| A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis 1% SPL7013 Gel, Placebo - Bacterial Vaginosis | Phase 3 | Completed | Starpharma Pty Ltd | 250 | 2012-03-28 | 2019-07-17 |
| A Pilot Open-label Randomized Study of Lactofiltrum in Women With Bacterial Vaginosis Lactofiltrum + Metronidazole, Metronidazole - Bacterial Vaginosis | Phase 2 / Phase 3 | Unknown | Avva Rus, JSC | 90 | 2010-07-01 | 2010-07-21 |
| Va-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery VA-SENSE - Vaginal Infections, Bacterial Vaginosis | Phase 3 | Unknown | Common Sense | 248 | 2010-07-01 | 2010-06-29 |
| The Impact of Probiotic Bacteria on the Efficacy of Anti-retroviral Therapy and Recurrence of Bacterial Vaginosis Yogurt supplemented with L. rhamnosus fiti, Yogurt not supplemented with a probiotic strain. - Bacterial Vaginosis | Phase 2 / Phase 3 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 150 | 2010-06-01 | 2010-12-13 |
Showing 20 of 32. Sign in to see all of them.
Vaginosis, Bacterial (32) · Vaginitis (4) · Premature Birth (3) · Candidiasis (2) · Candidiasis, Vulvovaginal (2) · Chlamydia Infections (2) · Gonorrhea (2) · HIV Infections (2) · Trichomonas Vaginitis (2) · Acquired Immunodeficiency Syndrome (1) · Bacterial Infections (1) · Bronchopulmonary Dysplasia (1) · Communicable Diseases (1) · Diarrhea (1) · Herpes Genitalis (1)
Bacterial Infections and Mycoses (32) · Female Urogenital Diseases (32) · Female Urogenital Diseases and Pregnancy Complications (32) · Genital Diseases (32) · Genital Diseases, Female (32) · Infections (32) · Bacterial Infections (31) · Urogenital Diseases (31) · Vaginal Diseases (31) · Vaginitis (28) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Disease Attributes (3) · Immune System Diseases (3) · Mycoses (3)
Metronidazole (8) · astodrimer (4) · Clindamycin (2) · Amphotericin B (1) · Azithromycin (1) · Ceftriaxone (1) · Circumcision, Male (1) · Clotrimazole (1) · Dequalinium (1) · Dexamethasone (1) · Doxycycline (1) · Ketoconazole (1) · Nystatin (1) · Tetracycline (1) · Tinidazole (1)
Starpharma Pty Ltd (4) · Symbiomix Therapeutics (2) · Actavis Inc. (1) · Amvac Kft. (1) · Assistance Publique Hopitaux De Marseille (1) · Avva Rus, JSC (1) · Balmoral Medical company (1) · Common Sense (1) · Daré Bioscience, Inc. (1) · Ege University (1) · Embil Pharmaceutical Co. Ltd (1) · Jeremy Burton (1) · Johns Hopkins Bloomberg School of Public Health (1) · Kaneka Americas Holding Inc. (1) · Laboratoires Lyocentre (1)
United States (11) · Brazil (3) · Canada (2) · Czechia (2) · Hungary (2) · Puerto Rico (2) · Tanzania (2) · Belgium (1) · Bulgaria (1) · Dominican Republic (1) · France (1) · Germany (1) · Ghana (1) · Guinea (1) · Israel (1)
Jeremy Paull, PhD (2) · Jeremy Paull, PhD. (2) · David Serwadda, MBChB,MPH (1) · Ernst Rainer Weissenbacher, MD (1) · Godfrey Kigozi, MBChB, MPH (1) · Jacques Pepin, MD (1) · Jermy Burton (1) · John Changalucha, MSc (1) · Kate V Meriwether, MD (1) · Konia Trouton, MD (1) · Leticia Krauss-Silva, MD, Ph.D (1) · Lyudmila Kobeleva, MD, PhD (1) · Melinda Zeron Mullins, MD, Ph.D (1) · Nicodemus Butamanya, MD (1)
PMID 17128343, PMID 17666604, PMID 18532873, PMID 19220138, PMID 19321868, PMID 19389002, PMID 19616720, PMID 19936044, PMID 20370481, PMID 20591191, PMID 20801446, PMID 21216000, PMID 21489882, PMID 22059409, PMID 22205034, PMID 25935783, PMID 26210791, PMID 26611782, PMID 29474292, PMID 30002871, PMID 30807423, PMID 33207004, PMID 35675606, PMID 37098453
2023 (1)